Motoric Cognitive Risk syndrome (MCR) is a pre-dementia syndrome characterized by the presence of cognitive complaints and slow gait.1, 2, 5 MCR predicts risk of developing Alzheimer’s disease (AD) and vascular dementia even after accounting for overlap with Mild Cognitive Impairment syndrome (MCI).1, 2, 5 MCR has incremental predictive validity for dementia over its individual cognitive and motoric components.1, 2 MCR is common; prevalence was 9.7% in a 17-country study with ~26,000 seniors.2 Unlike MCI, cognitive tests or complex lab assays are not required to diagnose MCR,1, 2, 5 increasing clinical utility. However, the pathogenesis of MCR is yet to be established.
To address this knowledge gap, we propose to examine the biology of MCR in ~11,000 older adults from 8 cohorts in USA (Central Control of Mobility in Aging: CCMA6, 7; Einstein Aging Study: EAS1; LonGenity5, 8), Canada (Quebec Longitudinal Study on Nutrition and Aging: NuAge9-12), Europe (Gait and Alzheimer Interactions Tracking: GAIT13), Asia (Kerala-Einstein study: KES4, National Center for Geriatrics and Gerontology-Study of Geriatric Syndromes: NCGG-SGS14) and Australia (Tasmanian Study of Cognition and Gait: TASCOG15). The MCR consortium has collaborated, shared and harmonized data, and published on MCR.1, 2, 4, 5, 13-15 Clinical phenotypes, biological/genetic, and neuroimaging data are available in our multi-ethnic consortium; a time and cost efficient approach to examine biology of MCR. Our MCR consortium will leverage these 8 cohorts to study pathogenesis of AD and related dementias via the MCR pathway in ~11,000 community-dwelling older adults. Our proposal is highly responsive to PAR-17-054, which encourages “combining cohorts (or consortia), to use and/or harmonize existing data, to collect data on new variables not present in all cohorts, to add new participants, or to link participants to administrative data.”